Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujin Hoshida

Showing results (81-90 of 263) with videos related to

Pageof 27
Sort By:
Eclinicalmedicine|September 5, 2024
Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosisSzu-Yu Zoe Kao, Kinpritma Sangha, Naoto Fujiwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2010
New strategies in hepatocellular carcinoma: genomic prognostic markersAugusto Villanueva, Yujin Hoshida, Sara Toffanin, et al.
Nature Reviews. Urology|November 23, 2016
The role of GATA2 in lethal prostate cancer aggressivenessVeronica Rodriguez-Bravo, Marc Carceles-Cordon, Yujin Hoshida, et al.
Gastroenterology|January 6, 2005
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathwaysRun-Xuan Shao, Motoyuki Otsuka, Naoya Kato, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemicHiroyuki Suzuki, Naoto Fujiwara, Amit G Singal, et al.
The American Journal of Pathology|August 5, 2024
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic SignificanceRocio I R Macias, Hiroaki Kanzaki, Carmen Berasain, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2021
Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic HepatitisNaoto Fujiwara, Eric Trépo, Indu Raman, et al.
Journal of Clinical Medicine|December 1, 2020
Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational ChallengesShen Li, Antonio Saviano, Derek J Erstad, et al.
Scientific Reports|July 25, 2019
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinomaKenichiro Enooku, Hayato Nakagawa, Naoto Fujiwara, et al.
Hepatology (Baltimore, Md.)|April 9, 2017
Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signatureAtsushi Ono, Nicolas Goossens, Richard S Finn, et al.
Pageof 27

Showing results (81-90 of 263) with videos related to

Sort By:
Pageof 27
Eclinicalmedicine|September 5, 2024
Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosisSzu-Yu Zoe Kao, Kinpritma Sangha, Naoto Fujiwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2010
New strategies in hepatocellular carcinoma: genomic prognostic markersAugusto Villanueva, Yujin Hoshida, Sara Toffanin, et al.
Nature Reviews. Urology|November 23, 2016
The role of GATA2 in lethal prostate cancer aggressivenessVeronica Rodriguez-Bravo, Marc Carceles-Cordon, Yujin Hoshida, et al.
Gastroenterology|January 6, 2005
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathwaysRun-Xuan Shao, Motoyuki Otsuka, Naoya Kato, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemicHiroyuki Suzuki, Naoto Fujiwara, Amit G Singal, et al.
The American Journal of Pathology|August 5, 2024
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic SignificanceRocio I R Macias, Hiroaki Kanzaki, Carmen Berasain, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2021
Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic HepatitisNaoto Fujiwara, Eric Trépo, Indu Raman, et al.
Journal of Clinical Medicine|December 1, 2020
Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational ChallengesShen Li, Antonio Saviano, Derek J Erstad, et al.
Scientific Reports|July 25, 2019
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinomaKenichiro Enooku, Hayato Nakagawa, Naoto Fujiwara, et al.
Hepatology (Baltimore, Md.)|April 9, 2017
Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signatureAtsushi Ono, Nicolas Goossens, Richard S Finn, et al.
Pageof 27